

# Per Kogner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3450192/publications.pdf>

Version: 2024-02-01

90  
papers

4,048  
citations

109321

35  
h-index

123424

61  
g-index

91  
all docs

91  
docs citations

91  
times ranked

4782  
citing authors

#	ARTICLE	IF	CITATIONS
1	Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 500-514.	10.7	256
2	High incidence of DNA mutations and gene amplifications of the <i>ALK</i> gene in advanced sporadic neuroblastoma tumours. <i>Biochemical Journal</i> , 2008, 416, 153-159.	3.7	246
3	Meta-analysis of Neuroblastomas Reveals a Skewed <i>ALK</i> Mutation Spectrum in Tumors with <i>MYCN</i> Amplification. <i>Clinical Cancer Research</i> , 2010, 16, 4353-4362.	7.0	243
4	High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 4323-4328.	7.1	200
5	Emergence of New <i>ALK</i> Mutations at Relapse of Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 2727-2734.	1.6	176
6	Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. <i>Cancer Research</i> , 1993, 53, 2044-50.	0.9	165
7	RASSF1A promoter region CpG island hypermethylation in pheochromocytomas and neuroblastoma tumours. <i>Oncogene</i> , 2001, 20, 7573-7577.	5.9	127
8	Sense-Antisense lncRNA Pair Encoded by Locus 6p22.3 Determines Neuroblastoma Susceptibility via the USP36-CHD7-SOX9 Regulatory Axis. <i>Cancer Cell</i> , 2018, 33, 417-434.e7.	16.8	122
9	Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 3516-3524.	1.6	114
10	Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma. <i>Clinical Cancer Research</i> , 2016, 22, 3849-3859.	7.0	109
11	Cyclooxygenase-2 Is Expressed in Neuroblastoma, and Nonsteroidal Anti-Inflammatory Drugs Induce Apoptosis and Inhibit Tumor Growth In vivo. <i>Cancer Research</i> , 2004, 64, 7210-7215.	0.9	105
12	Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies. <i>Nature Medicine</i> , 2017, 23, 256-263.	30.7	102
13	Single-cell transcriptomics of human embryos identifies multiple sympathoblast lineages with potential implications for neuroblastoma origin. <i>Nature Genetics</i> , 2021, 53, 694-706.	21.4	90
14	COX/mPGES-1/PGE <sub>2</sub> pathway depicts an inflammatory-dependent high-risk neuroblastoma subset. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8070-8075.	7.1	88
15	High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: Four cases of homozygous deletions of the CDKN2A gene. <i>BMC Genomics</i> , 2008, 9, 353.	2.8	84
16	Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy. <i>Cancer Research</i> , 2011, 71, 98-105.	0.9	80
17	Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors. <i>Epigenetics</i> , 2016, 11, 74-84.	2.7	63
18	Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma. <i>Carcinogenesis</i> , 2013, 34, 1081-1088.	2.8	60

#	ARTICLE	IF	CITATIONS
19	Inhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth. <i>EBioMedicine</i> , 2018, 32, 84-92.	6.1	60
20	Cell culture and <i>Drosophila</i> model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma. <i>DMM Disease Models and Mechanisms</i> , 2013, 6, 373-82.	2.4	59
21	Embryonal neural tumours and cell death. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2009, 14, 424-438.	4.9	57
22	Celecoxib Prevents Neuroblastoma Tumor Development and Potentiates the Effect of Chemotherapeutic Drugs In vitro and In vivo. <i>Clinical Cancer Research</i> , 2007, 13, 1036-1044.	7.0	56
23	Dual Targeting of Wild-Type and Mutant p53 by Small Molecule RITA Results in the Inhibition of N-Myc and Key Survival Oncogenes and Kills Neuroblastoma Cells <i>In Vivo</i> and <i>In Vitro</i> . <i>Clinical Cancer Research</i> , 2013, 19, 5092-5103.	7.0	55
24	Risk stratification of high-risk metastatic neuroblastoma: A report from the HRNBL1/SIOPEN study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27363.	1.5	53
25	Rho-associated kinase is a therapeutic target in neuroblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E6603-E6612.	7.1	52
26	Delimitation of a critical tumour suppressor region at distal 1p in neuroblastoma tumours. <i>European Journal of Cancer</i> , 1997, 33, 1997-2001.	2.8	49
27	Combined <sup>111</sup> In-pentetreotide scintigraphy and <sup>123</sup> I-mIBG scintigraphy in neuroblastoma provides prognostic information. <i>Medical and Pediatric Oncology</i> , 2000, 35, 688-691.	1.0	48
28	Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade. <i>Oncolmmunology</i> , 2016, 5, e1232222.	4.6	48
29	Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002550.	1.2	47
30	Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2 (SSTR2) gene at 17q24. <i>British Journal of Cancer</i> , 1999, 81, 1402-1409.	6.4	46
31	Intragenic anaplastic lymphoma kinase ( <i>ALK</i> ) rearrangements: Translocations as a novel mechanism of <i>ALK</i> activation in neuroblastoma tumors. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 99-109.	2.8	45
32	Tumor Development, Growth Characteristics and Spectrum of Genetic Aberrations in the TH-MYCN Mouse Model of Neuroblastoma. <i>PLoS ONE</i> , 2012, 7, e51297.	2.5	43
33	Integrative discovery of treatments for high-risk neuroblastoma. <i>Nature Communications</i> , 2020, 11, 71.	12.8	42
34	Somatostatin in neuroblastoma and ganglioneuroma. <i>European Journal of Cancer</i> , 1997, 33, 2084-2089.	2.8	41
35	Single-nuclei transcriptomes from human adrenal gland reveal distinct cellular identities of low and high-risk neuroblastoma tumors. <i>Nature Communications</i> , 2021, 12, 5309.	12.8	38
36	The use of fine-needle aspiration cytology in the molecular characterization of neuroblastoma in children. <i>Cancer</i> , 1999, 87, 60-68.	4.1	37

#	ARTICLE	IF	CITATIONS
37	Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors. <i>BMC Genomics</i> , 2011, 12, 443.	2.8	33
38	The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes. <i>Oncolmmunology</i> , 2013, 2, e23618.	4.6	32
39	Fine mapping of a tumour suppressor candidate gene region in 1p36.2-3, commonly deleted in neuroblastomas and germ cell tumours. <i>Medical and Pediatric Oncology</i> , 2001, 36, 61-66.	1.0	31
40	Neuropeptide Y in neuroblastoma: Increased concentration in metastasis, release during surgery, and characterization of plasma and tumor extracts. <i>Medical and Pediatric Oncology</i> , 1993, 21, 317-322.	1.0	30
41	Frequency and Prognostic Impact of <i>ALK</i> Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). <i>Journal of Clinical Oncology</i> , 2021, 39, 3377-3390.	1.6	30
42	N-myc Gene Amplification in Neuroblastoma: A Clinical Approach Using Ultrasound Guided Cutting Needle Biopsies Collected at Diagnosis. <i>Medical and Pediatric Oncology</i> , 1992, 20, 292-300.	1.0	29
43	Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1-11.	5.0	28
44	Neuropeptide Y (NPY) synthesis in lymphoblasts and increased plasma NPY in pediatric B-cell precursor leukemia. <i>Blood</i> , 1992, 80, 1324-1329.	1.4	27
45	Plasma neuropeptide Y in healthy children: influence of age, anaesthesia and the establishment of an age-adjusted reference interval. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1994, 83, 423-727.	1.5	27
46	The vitamin A analogues: 13-cis retinoic acid, 9-cis retinoic acid, and Ro 13-6307 inhibit neuroblastoma tumour growth in vivo. <i>Medical and Pediatric Oncology</i> , 2001, 36, 127-131.	1.0	27
47	11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma. <i>Cell Reports</i> , 2020, 32, 108171.	6.4	25
48	Promoter-specific methylation and expression alterations of <i>igf2</i> and <i>h19</i> are involved in human hepatoblastoma. , 1998, 75, 176-180.		24
49	Monosomy 1p36.31-33pter due to a paternal reciprocal translocation: Prognostic significance of FISH analysis. , 1996, 65, 60-67.		22
50	Subcellular Distribution of p53 by the p53-Responsive lncRNA <i>NBAT1</i> Determines Chemotherapeutic Response in Neuroblastoma. <i>Cancer Research</i> , 2021, 81, 1457-1471.	0.9	22
51	Neuropeptide Y as a Marker in Pediatric Neuroblastoma. <i>Pediatric Pathology</i> , 1990, 10, 207-216.	0.5	21
52	Planar cell polarity gene expression correlates with tumor cell viability and prognostic outcome in neuroblastoma. <i>BMC Cancer</i> , 2016, 16, 259.	2.6	20
53	Regulation of Nuclear Hormone Receptors by MYCN-Driven miRNAs Impacts Neural Differentiation and Survival in Neuroblastoma Patients. <i>Cell Reports</i> , 2016, 16, 979-993.	6.4	19
54	Chapter 18 Neuropeptides in neuroblastomas and ganglioneuromas. <i>Progress in Brain Research</i> , 1995, 104, 325-338.	1.4	18

#	ARTICLE	IF	CITATIONS
55	Assessment of <i>NORE1A</i> as a putative tumor suppressor in human neuroblastoma. <i>International Journal of Cancer</i> , 2008, 123, 389-394.	5.1	18
56	Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and CIC in neuroblastoma. <i>International Journal of Oncology</i> , 2016, 48, 1103-1116.	3.3	18
57	Analysis of <i>ALK</i> , <i>MYCN</i> , and the ALK ligand <i>ALKAL2</i> ( <i>FAM150B/AUG1±</i> ) in neuroblastoma patient samples with chromosome arm 2p rearrangements. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 50-57.	2.8	18
58	Establishment of an in vitro 3D model for neuroblastoma enables preclinical investigation of combined tumor-estroma drug targeting. <i>FASEB Journal</i> , 2020, 34, 11101-11114.	0.5	18
59	The Somatostatin Analogue Octreotide Inhibits Neuroblastoma Growth in Vivo. <i>Pediatric Research</i> , 1999, 46, 328-332.	2.3	18
60	Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors. <i>Pediatric Hematology and Oncology</i> , 2018, 35, 156-165.	0.8	17
61	The immune cell atlas of human neuroblastoma. <i>Cell Reports Medicine</i> , 2022, 3, 100657.	6.5	17
62	Pancreastatin immunoreactivity in favourable childhood neuroblastoma and ganglioneuroma. <i>European Journal of Cancer</i> , 1995, 31, 557-560.	2.8	14
63	Neuroblastoma-related inflammation. <i>Oncolmmunology</i> , 2013, 2, e24658.	4.6	14
64	Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment. <i>Scientific Reports</i> , 2019, 9, 2199.	3.3	14
65	Aberrant splicing in neuroblastoma generates RNA-fusion transcripts and provides vulnerability to spliceosome inhibitors. <i>Nucleic Acids Research</i> , 2021, 49, 2509-2521.	14.5	12
66	Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEX Biology Group on the LNESG Trials and a COG Validation Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 3685-3697.	1.6	9
67	Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation. <i>JCO Precision Oncology</i> , 2022, 6, e2100271.	3.0	8
68	Improved Local Control by Extensive Surgery in High-Risk Neuroblastoma May Be Dependent on Adjuvant Radiotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1965-1966.	1.6	7
69	Expression of nerve growth factor receptor mRNAs and clinical response to retinoic acid in neuroblastoma. <i>Progress in Clinical and Biological Research</i> , 1994, 385, 147-53.	0.2	7
70	Soluble factors released by activated cytotoxic T lymphocytes interfere with death receptor pathways in neuroblastoma. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 731-743.	4.2	6
71	High Expression of PPM1D Induces Tumors Phenotypically Similar to TP53 Loss-of-Function Mutations in Mice. <i>Cancers</i> , 2021, 13, 5493.	3.7	6
72	What can we expect from neuroblastoma screening? Clinicians point of view. <i>Medical and Pediatric Oncology</i> , 1998, 31, 408-418.	1.0	5

#	ARTICLE	IF	CITATIONS
73	Absence of somatostatin receptor expression in vivo is correlated to di- or tetraploid 1p36-deleted neuroblastomas. <i>Medical and Pediatric Oncology</i> , 2001, 36, 56-60.	1.0	5
74	Whole-body MRI within a surveillance program for carriers with clinically actionable germline TP53 variants - the Swedish constitutional TP53 study SWEP53. <i>Hereditary Cancer in Clinical Practice</i> , 2020, 18, 1.	1.5	5
75	PPM1D Is a Therapeutic Target in Childhood Neural Tumors. <i>Cancers</i> , 2021, 13, 6042.	3.7	5
76	Omega-3 fatty acids decrease CRYAB, production of oncogenic prostaglandin E2 and suppress tumor growth in medulloblastoma. <i>Life Sciences</i> , 2022, 295, 120394.	4.3	5
77	Neuropeptide Y (NPY) synthesis in lymphoblasts and increased plasma NPY in pediatric B-cell precursor leukemia. <i>Blood</i> , 1992, 80, 1324-9.	1.4	5
78	Screening for neuroblastoma: ethical and psychological aspects. <i>Medical and Pediatric Oncology</i> , 1998, 31, 421-425.	1.0	3
79	Body surface area-based omega-3 fatty acids supplementation strongly correlates to blood concentrations in children.. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2021, 169, 102285.	2.2	3
80	Immunotherapy (IT) with ch14.18/CHO for high-risk neuroblastoma: First results from the randomised HR-NBL1/SIOPEN trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10026-10026.	1.6	3
81	Plasma neuropeptide Y (NPY): a novel marker of neuroblastoma. <i>Progress in Clinical and Biological Research</i> , 1991, 366, 367-73.	0.2	3
82	The use of fine-needle aspiration cytology in the molecular characterization of neuroblastoma in children. <i>Cancer</i> , 1999, 87, 60-68.	4.1	2
83	Prognostic factors in stage 4 neuroblastoma treated with busulphan-melphalan: Report from the European HR-NBL1/Siopen trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10527-10527.	1.6	1
84	Filamin A increases aggressiveness of human neuroblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac028.	0.7	1
85	Venetoclax in cancer therapy and potential effects on bone. <i>Lancet Oncology</i> , The, 2016, 17, e319-e320.	10.7	0
86	Neuropeptide Y (NPY) synthesis in lymphoblasts and increased plasma NPY in pediatric B-cell precursor leukemia. <i>Blood</i> , 1992, 80, 1324-1329.	1.4	0
87	Emergence of new <i>ALK</i> mutations at relapse of neuroblastoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11006-11006.	1.6	0
88	11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
89	Characterization of neuropeptide Y in pediatric neural crest tumors: relation to tumor malignancy and genetic findings. <i>Progress in Clinical and Biological Research</i> , 1991, 366, 351-7.	0.2	0
90	TC-hunter: identification of the insertion site of a transgenic gene within the host genome. <i>BMC Genomics</i> , 2022, 23, 149.	2.8	0